Sivik Global Healthcare LLC lessened its holdings in Baxter International Inc. (NYSE:BAX) by 9.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100,000 shares of the medical instruments supplier’s stock after selling 10,000 shares during the period. Baxter International comprises 2.2% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 16th biggest holding. Sivik Global Healthcare LLC’s holdings in Baxter International were worth $6,054,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Baker Ellis Asset Management LLC acquired a new stake in shares of Baxter International in the 2nd quarter worth about $109,000. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Baxter International by 6.1% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 2,533 shares of the medical instruments supplier’s stock worth $131,000 after acquiring an additional 145 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its holdings in shares of Baxter International by 3.9% in the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 2,776 shares of the medical instruments supplier’s stock worth $144,000 after acquiring an additional 103 shares during the last quarter. Captrust Financial Advisors acquired a new stake in shares of Baxter International in the 2nd quarter worth about $188,000. Finally, Trust Co. of Vermont raised its holdings in shares of Baxter International by 8.7% in the 1st quarter. Trust Co. of Vermont now owns 3,282 shares of the medical instruments supplier’s stock worth $170,000 after acquiring an additional 262 shares during the last quarter. Institutional investors own 83.71% of the company’s stock.

In other news, SVP Giuseppe Accogli sold 12,670 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $60.96, for a total transaction of $772,363.20. Following the completion of the transaction, the senior vice president now directly owns 33,286 shares of the company’s stock, valued at $2,029,114.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Carole J. Shapazian sold 4,020 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $61.61, for a total transaction of $247,672.20. Following the transaction, the director now directly owns 13,868 shares of the company’s stock, valued at $854,407.48. The disclosure for this sale can be found here. Insiders have sold 35,050 shares of company stock valued at $2,158,587 over the last three months. 0.05% of the stock is owned by corporate insiders.

Shares of Baxter International Inc. (NYSE:BAX) traded down 0.56% during midday trading on Friday, hitting $63.96. 4,525,594 shares of the stock traded hands. Baxter International Inc. has a 52 week low of $43.13 and a 52 week high of $64.75. The company’s 50-day moving average is $61.50 and its 200 day moving average is $57.69. The firm has a market capitalization of $34.85 billion, a PE ratio of 38.81 and a beta of 0.66.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Wednesday, July 26th. The medical instruments supplier reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.06. Baxter International had a net margin of 8.85% and a return on equity of 14.82%. The firm had revenue of $2.61 billion during the quarter, compared to analysts’ expectations of $2.59 billion. During the same period in the previous year, the company earned $0.46 earnings per share. The firm’s quarterly revenue was up .8% on a year-over-year basis. Analysts anticipate that Baxter International Inc. will post $2.39 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 2nd. Stockholders of record on Friday, September 1st will be issued a dividend of $0.16 per share. The ex-dividend date is Wednesday, August 30th. This represents a $0.64 annualized dividend and a dividend yield of 1.00%. Baxter International’s payout ratio is 38.79%.

A number of equities research analysts recently weighed in on BAX shares. Cantor Fitzgerald set a $70.00 target price on shares of Baxter International and gave the stock a “buy” rating in a report on Wednesday, July 26th. BidaskClub lowered shares of Baxter International from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research lowered shares of Baxter International from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Stifel Nicolaus increased their price objective on shares of Baxter International from $58.00 to $61.00 and gave the company a “hold” rating in a research note on Wednesday, May 31st. Finally, Royal Bank Of Canada reiterated a “hold” rating and issued a $60.00 price objective on shares of Baxter International in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $65.31.

TRADEMARK VIOLATION WARNING: This article was originally published by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.dailypolitical.com/2017/09/17/sivik-global-healthcare-llc-has-6-05-million-position-in-baxter-international-inc-bax.html.

Baxter International Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc. (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.